Présentation de l'entreprise
Innate Pharma S.A. operates within the healthcare sector, specifically functioning as a biotechnology company dedicated to the development of immunotherapies for cancer patients in France and international markets. The firm focuses on innovative product pipelines, notably including Lacutamab (IPH4102), an anti-KIR3DL2 antibody currently undergoing Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphomas. As of the latest reporting period, the company maintains a market capitalization of $136.00M, generating $9.01M in annual revenue while employing a workforce of 163 individuals. These financial metrics indicate that Innate Pharma is a small-cap entity with a market valuation significantly higher than its current revenue base, a characteristic often observed in early-stage biotechnology firms where future clinical milestones and regulatory approvals are the primary drivers of enterprise value rather than current cash flows.
Santé financière
The company reported a revenue of $9.01M over the trailing twelve months, yet this figure stands in stark contrast to a net income of $-49,177,000 and an EBITDA of $-52,625,000. The substantial gap between the positive revenue stream and the deeply negative net income reveals a cost structure dominated by high research and development expenditures and clinical trial costs typical of the biotechnology industry, where revenue recognition is often delayed until commercialization. This financial reality is further evidenced by a free cash flow of $-33,798,624, indicating that the company is burning cash to fund its operations and pipeline development, which limits immediate financial flexibility but is a standard strategic requirement for advancing drug candidates. Profitability metrics reflect this developmental stage, with a gross margin of 0.0%, an operating margin of -689.6%, and a profit margin of 0.0%, all signaling that the business model is currently structured to prioritize R&D investment over immediate profit generation. On the balance sheet, the company holds $34.31M in cash against $22.57M in debt, creating a net cash position, although the debt-to-equity ratio is listed as N/A due to the negative equity implied by the losses. Liquidity is supported by a current ratio of 1.27, suggesting the company possesses sufficient current assets to cover its short-term liabilities without immediate distress. Finally, the return on equity is N/A and the return on assets stands at -38.8%, metrics that collectively reveal that management effectiveness, in terms of generating returns, is currently challenged by the heavy capital requirements inherent in developing immunotherapy assets.
Évaluation de la valorisation
The valuation profile of Innate Pharma is complex, featuring a trailing P/E ratio of N/A and a forward P/E of -2.31, a discrepancy that implies earnings are currently negative and traditional trailing multiples are not applicable, while the negative forward multiple suggests a market expectation of potential future earnings recovery or a specific accounting treatment for upcoming revenue. The price-to-book ratio is -5.33, a negative figure indicating that the market values the company at a level that does not align with its book value, likely due to the intangible nature of its clinical pipeline assets which are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 15.10 and an EV/EBITDA of -2.32 are critical for assessing the firm, as they highlight that investors are pricing the stock based on sales generation potential rather than current profitability or cash earnings. The stock has traded within a range defined by a 52-week high of $2.63 and a 52-week low of $1.17, providing a context for price volatility that investors must consider when analyzing the current share price relative to these historical extremes. The beta value of 0.74 indicates that the stock's price volatility is lower than that of the broader market, suggesting a defensive characteristic relative to the high-risk nature of its biotechnology sector peers.
Growth & Income
Revenue growth for the trailing twelve months was -46.7% year-over-year, while earnings growth is listed as N/A due to the company's ongoing losses, a situation where the contraction in revenue highlights a decline in commercial sales or contract income rather than a lack of product pipeline progress. Since the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, Innate Pharma reinvests its limited earnings and cash reserves entirely into research and development efforts rather than distributing income to shareholders. The absence of dividend payouts is consistent with the company's lifecycle stage, where capital preservation and pipeline advancement take precedence over income generation for existing shareholders. Overall, the growth and income profile of Innate Pharma is characterized by revenue contraction and zero dividend yield, reflecting a strategic focus on long-term asset development rather than short-term financial returns or income distribution.